Nephrology

Experts discuss the intricate relationship between diabetes, kidney disease, and cardiovascular function and explore the evolving landscape of therapies with cardiorenal benefits.

The FDA has issued a Class I recall for some of Fresenius Medical Care's hemodialysis machines due to potential exposure to toxic compounds, affecting eight specific models from the 2008 Series.

An expert nephrologist provides an overview of the pathophysiology of IgAN before discussing new immunomodulating therapies in clinical trials.

Chee Kay Cheung, MBCHB, MRCP, PhD, discusses unmet needs in the management of IgAN, commenting on the need for new medication and highlighting budesonide and SGLT2 inhibitors.

On October 17, 2023, Ardelyx Inc announced the FDA approval of tenapanor (Xphozah) for reducing serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy.

Patients with IgA nephropathy experienced nearly 30% proteinuria reduction after 6 months of treatment with SGLT2 inhibitors.

An expert nephrologist shares his opinion on newer treatments of IgAN such as budesonide and SGLT2 inhibitors, commenting that patients with greater disease progression stand to benefit the most from these treatments.

Chee Kay Cheung, MBCHB, MRCP, PhD, reviews newly approved agents for the treatment of IgAN, focusing on SGLT2 inhibitors, budesonide, and sparsentan.

Findings showed the probability of achieving total remission was significantly greater in the corticosteroid pulse group compared to the oral corticosteroid group.

On October 10, 2023, Novo Nordisk announced they would be stopping the FLOW trial, which examined the effects of semaglutide 1.0 mg on kidney outcomes in type 2 diabetes, due to early efficacy based on an interim analysis of the trial.

Syed Ali Husain, MD, MPH, discusses the importance of kidney transplantation, waitlisting, and how disparities in access to transplantation should be addressed.

Chee Kay Cheung, MBCHB, MRCP, PhD, comments on optimized supportive care for patients with IgAN, which monitors things like blood pressure, diet, and lifestyle.

Chee Kay Cheung, MBCHB, MRCP, PhD, reviews the disease burden and prevalence of immunoglobulin A nephropathy (IgAN), as well as risk factors for disease progression.

This installment in our Unprevented series examines the growing impact of chronic kidney disease on public health and what those in the field are doing to mitigate this growing crisis.

Interim results from the phase 3 APPLAUSE-IgAN study showed a statistically significant reduction in proteinuria among patients treated with iptacopan compared to placebo.

Findings from a meta-analysis are calling attention to the viability of classification and risk stratification using greater albuminuria and decreased eGFR.

Among a cohort of young patients with no major comorbidity burdens, 49% were not waitlisted within 5 years of dialysis initiation.

Positive findings from NefIgArd demonstrated budesonide’s ability to modulate the intestinal immune network responsible for IgA production.

A 20-year analysis reveals over 25% of US adults have cardiac, renal, or metabolic conditions, with disparities in age and race.

Eli Lilly and Company and Boehringer Ingelheim announced the FDA approval of empagliflozin (Jardiance) for chronic kidney disease management on September 22, 2023.

Citing more than half a dozen major trials in the 2 years since the release of their 2021 heart failure guidelines, the European Society of Cardiology has released a focused update to their heart failure guidance.

Investigators identified a strong magnitude of association between MAFLD and risk of CKD based on the results of a comprehensive meta-analysis.

An analysis of data from CREDENCE provides insight into the prognostic potential of a group of 4 common biomarkers for predicting cardiovascular and kidney issues in people with type 2 diabetes.

CKD-aP patients receiving maintenance hemodialysis reported adverse clinical events in line with their pruritus severity and were found to be at greater risk of all-cause mortality, all-cause hospitalization, and cardiovascular events.

Phase 3 data show a significant clinical profile associated with durable reductions in IgA nephropathy biomarkers among patients treated with Nefecon.